CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer

British Journal of Clinical Pharmacology

Volumn 78, Issue 2, 2014, Pages 431-432

  Damkier, Per ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; PAROXETINE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

BREAST CANCER; CANCER CHEMOTHERAPY; DRUG EFFECT; GENOTYPE; GERM LINE; HUMAN; LETTER; META ANALYSIS (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; BREAST NEOPLASMS; FEMALE; GENETICS; METABOLISM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84904907447     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12329     Document Type: Letter

References (10)

1. Brauch H, Schwab M,. Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. Br J Clin Pharmacol 2014; 77: 695-703.
2. Rae JM, Regan MM, Thibert JN, Gersch C, Thomas D, Leyland-Jones B, Viale G, Pusztai L, Hayes DF, Skaar T, Van Poznak C,. Concordance between CYP2D6 genotypes obtained from tumor-derived and germ-line DNA. J natl Cancer Inst 2013; 105: 1332-1334.
3. Ahern TP, Christensen M, Cronin-Fenton DP, Lunetta KL, Rosenberg CL, Sørensen HT, Lash TL, Hamilton-Dutoit S,. Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol 2012; 2: 241-246.
4. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF,. Selective serotonin reuptake inhibitors and breast cancer mortality in patients receiving tamoxifen: a population based cohort study. BMJ 2010; 340: c693.
5. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sørensen HT, Hellberg Y, Christensen M, Pedersen L, Hamilton-Dutoit S,. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst 2011; 103: 489-500.
6. Berry B,. CYP2D6 genotyping and the use of tamoxifen in breast cancer. J Natl Cancer Inst 2013; 105: 1267-1269.
7. Rae JM,. CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients. Clin Pharmacol Ther 2013; 94: 183-185.
8. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H,. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-1436.
9. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN,. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-9318.
10. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Michael Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonné AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE,. CYP2D6 genotype and adjuvant tamoxifen tamoxifen. Meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 2013; 95: 216-227.